SCHEMBL27214770

SCHEMBL27214770

CCCCCCCCCCCCC(CCCCCCCCCCC(CCCCCCCCCCCC)c1ccc(S(=O)(=O)O)cc1)c1ccc(S(=O)(=O)O)cc1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 1/20 0.63
S1PR3 Q99500 2/20 0.43
TP53 P04637 1/20 0.41
MMP9 P14780 2/20 0.40
MMP13 P45452 2/20 0.40
ADAM17 P78536 2/20 0.40
MMP1 P03956 2/20 0.40
CA2 P00918 3/20 0.39
MMP2 P08253 1/20 0.39
MMP3 P08254 1/20 0.39
S1PR2 O95136 1/20 0.38
S1PR1 P21453 1/20 0.38
LMNA P02545 1/20 0.38
NAAA Q02083 2/20 0.38
ALDH1A1 P00352 1/20 0.37
TSHR P16473 1/20 0.37
NT5E P21589 1/20 0.37
CNR2 P34972 1/20 0.37
SERPINE1 P05121 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19627845 1.00 NR1I2 (0.63) NR1I2S1PR3TP53MMP9MMP13
SCHEMBL6128184 1.00 NR1I2 (0.63) NR1I2S1PR3TP53MMP9MMP13
SCHEMBL4310857 1.00 NR1I2 (0.63) NR1I2S1PR3TP53MMP9MMP13
SCHEMBL14801970 0.98 NR1I2 (0.61) NR1I2S1PR3TP53MMP9MMP13
SCHEMBL19627843 0.98 NR1I2 (0.61) NR1I2S1PR3TP53MMP9MMP13
SCHEMBL15936841 0.97 NR1I2 (0.60) NR1I2S1PR3TP53MMP9MMP13
Ammonia Solution, Strong SCHEMBL28300034 0.97 NR1I2 (0.60) NR1I2S1PR3TP53MMP9MMP13
SCHEMBL16324578 0.97 NR1I2 (0.60) NR1I2S1PR3TP53MMP9MMP13
SCHEMBL16076634 0.97 NR1I2 (0.59) NR1I2S1PR3TP53MMP9MMP13
SCHEMBL1048442 0.94 NR1I2 (0.73) NR1I2S1PR3TP53MMP9MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240148753-A1 METHOD AND COMPOSITION FOR REVERSING AND/OR INHIBITING ATHEROSCLEROSIS Arjil Biotech Holding Company Limited (TW) 2024-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240148753-A1 METHOD AND COMPOSITION FOR REVERSING AND/OR INHIBITING ATHEROSCLEROSIS PCSK9, APOB, PCSK7 NR1I2 1247/4885S1PR3 1167/4885TP53 4605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.